Generic Medicine Info
May be taken with or without food. Incidence of minor indigestion may increase as dose increases. Take w/ meals if necessary.
Undiagnosed vaginal bleeding, previous idiopathic or current venous thromboembolism (e.g. DVT, pulmonary embolism); active or recent arterial thromboembolic disease (e.g. angina, MI) or cerebrovascular disease; missed abortion. Gynaecological/contraceptive use: Known, history or suspected breast cancer; porphyria; metabolic bone disease (SC). Hepatic impairment. Pregnancy.
Special Precautions
Patient with risk factors for estrogen-dependent tumours; history of or risk factors for thromboembolic disorders; hypertension, liver disorders (e.g. liver adenoma), cholelithiasis, history of liver disease, diabetes mellitus (with or without vascular involvement), migraine or severe headache, SLE, epilepsy, asthma, otosclerosis, cardiac dysfunction, history of acute visual disturbances or mental depression, hypercholesterolaemia; hypoparathyroidism (in combination with estrogen). Obesity. Risk factors for osteoporosis (e.g. chronic alcohol or tobacco use, low BMI, eating disorder, previous low trauma fracture, family history of osteoporosis). Renal impairment. Lactation. Discontinue combination therapy with estrogens at least 4-6 weeks prior to surgery associated with an increased risk of thromboembolism or within periods of prolonged immobilisation. Monitoring Parameters Obtain bone mineral density (prolonged use). Monitor blood pressure and glucose (in diabetic patients). Evaluate for vision loss, migraines, signs of thromboembolic disorders or depression. Contraceptive use: Verify pregnancy status prior to use. Monitor weight and assess potential health status changes.
Adverse Reactions
Significant: Decreased glucose tolerance, jaundice, increased blood pressure, new onset of migraine-type headache, weight gain, fluid retention; vaginal bleeding, depression, menstrual irregularities (e.g. amenorrhoea, unpredictable bleeding or spotting), Cushingoid symptoms, suppressed adrenal function, increased triglycerides (in women with pre-existing hypertriglyceridaemia), visual abnormalities, thromboembolic disorders, loss of bone mineral density, delayed return to ovulation and fertility (upon discontinuation), anaphylaxis or anaphylactoid reaction, severe abdominal pain (IM/SC). Gastrointestinal disorders: Nausea, vomiting, constipation; abdominal pain, distension, or discomfort. General disorders and administration site conditions: Pyrexia, fatigue; asthenia, inj site reaction (SC). Investigations: Weight decreased; abnormal smear cervix (SC). Metabolism and nutrition disorders: Hypercalcaemia (in treatment of breast carcinoma), increased appetite. Musculoskeletal and connective tissue disorders: Back pain, pain in extremity. Nervous system disorders: Headache, dizziness, tremors. Psychiatric disorders: Insomnia, nervousness, libido decreased. Reproductive system and breast disorders: Cervical discharge, breast pain or tenderness, erectile dysfunction, dysmenorrhea, genitourinary tract infection. Skin and subcutaneous tissue disorders: Urticaria, alopecia, acne, pruritus, hyperhidrosis. Vascular disorders: Hot flush.
Drug Interactions
Bioavailability may be decreased when used concomitantly with aminoglutethimide. May decrease plasma concentration with enzyme inducers including CYP3A4 (e.g. phenytoin, phenobarbital, carbamazepine, rifampicin, nevirapine). Concomitant use with ciclosporin may result in increased plasma levels of ciclosporin and/or decreased plasma levels of medroxyprogesterone. May decrease the haematological toxicity of cytotoxic agents. Increased risk of invasive breast cancer, dementia, and CV disease (e.g. DVT, pulmonary emboli, stroke) in postmenopausal women when used concomitantly with conjugated estrogens.
ATC Classification
L02AB02 - medroxyprogesterone ; Belongs to the class of progestogens.
G03AC06 - medroxyprogesterone ; Belongs to the class of progestogens. Used as systemic contraceptives.
G03DA02 - medroxyprogesterone ; Belongs to the class of pregnen (4) derivative progestogens.
Disclaimer: This information is independently developed by CIMS based on medroxyprogesterone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in